THE WIRE · № 74853
Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting
01 THE MACHINE READ
WHY IT MATTERS.
Positive Phase 3 results could support a US regulatory path for a P-CAB in NERD, but no approval or financials are stated.
Early positive NERD data, approval still uncertain
Regulatory submission or FDA decision timing
Trial data may not translate to approval
FULL DISPATCH
Key Highlights: Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial. Detailed analysis from the randomized, double-blind, placebo-controlled Phase 3...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 20262026-10-11 17:00 UTC
Humana surges after topping 2027 Medicare star ratings2026-10-09 18:15 UTC
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer2026-10-10 04:41 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.